

FOI 3614

27th February 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)**
- **Amivantamab Monotherapy**
- **Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only)**
- **Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel**
- **Atezolizumab monotherapy (subcutaneous injection only)**
- **Dabrafenib + Trametinib**
- **Docetaxel monotherapy or in combination with Carboplatin/Cisplatin**
- **Durvalumab**
- **Gemcitabine**
- **Nintedanib + Docetaxel**
- **Nivolumab**
- **Osimertinib**
- **Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)**
- **Paclitaxel**
- **Pembrolizumab Monotherapy**
- **Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)**
- **Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)**
- **Pemetrexed + Platinum (Carboplatin/Cisplatin)**
- **RET Inhibitors (Pralsetinib, Selpercatinib)**

- **Sotorasib**
- **Tepotinib**
- **Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**
- **Amivantamab with carboplatin and pemetrexed**
- **Cemiplimab with platinum-based chemotherapy**
- **Adagrasib**
- **Datopotamab deruxtecan**
- **Amivantamab with lazertinib**

Response:

No data is available from pharmacy sources as oncology chemotherapy is not dispensed in pharmacy through an electronic system that links the drugs dispensed to the diagnosed disease condition.

This information is not recorded centrally therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q2. Does your trust participate in any clinical trials for Non-Small Cell Lung Cancer? If so, please provide the name of each trial, and the number of patients taking part.

Response:

No participation currently in trials for Non-Small Cell Lung Cancer.

Email: Foi.Team@Southerntrust.hscni.net